CN114901317A - 双环肽配体药物偶联物 - Google Patents

双环肽配体药物偶联物 Download PDF

Info

Publication number
CN114901317A
CN114901317A CN202080071881.XA CN202080071881A CN114901317A CN 114901317 A CN114901317 A CN 114901317A CN 202080071881 A CN202080071881 A CN 202080071881A CN 114901317 A CN114901317 A CN 114901317A
Authority
CN
China
Prior art keywords
drug conjugate
peptide
acid
fibronectin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071881.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·贝斯维克
G·马德
M·里格比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of CN114901317A publication Critical patent/CN114901317A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080071881.XA 2019-10-15 2020-10-15 双环肽配体药物偶联物 Pending CN114901317A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1914872.5 2019-10-15
GB201914872A GB201914872D0 (en) 2019-10-15 2019-10-15 Bicyclic peptide ligand drug conjugates
PCT/GB2020/052590 WO2021074622A1 (en) 2019-10-15 2020-10-15 Bicyclic peptide ligand drug conjugates

Publications (1)

Publication Number Publication Date
CN114901317A true CN114901317A (zh) 2022-08-12

Family

ID=68619460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071881.XA Pending CN114901317A (zh) 2019-10-15 2020-10-15 双环肽配体药物偶联物

Country Status (12)

Country Link
US (1) US20240173422A1 (https=)
EP (1) EP4045089A1 (https=)
JP (1) JP2022552839A (https=)
KR (1) KR20220088416A (https=)
CN (1) CN114901317A (https=)
AU (1) AU2020367325A1 (https=)
BR (1) BR112022007099A2 (https=)
CA (1) CA3154672A1 (https=)
GB (1) GB201914872D0 (https=)
IL (1) IL292113A (https=)
MX (1) MX2022004572A (https=)
WO (1) WO2021074622A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003830A (zh) * 2023-08-04 2023-11-07 湖南中晟全肽生化有限公司 靶向Nectin-4的多肽及其用途
CN119701000A (zh) * 2024-12-25 2025-03-28 中国人民解放军空军军医大学 一类多肽偶联药物及其制备方法和应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
MX2024003876A (es) 2021-09-29 2024-04-19 Conjustar Zhuhai Biologics Co Ltd Conjugado farmaco-polipeptido triciclico y sus aplicaciones.
GB202114279D0 (en) * 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2023066314A1 (zh) * 2021-10-19 2023-04-27 海思科医药集团股份有限公司 Nectin-4的双环肽配体及其用途
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162682A1 (en) * 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019193328A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
IL279489B2 (en) * 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162682A1 (en) * 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019193328A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003830A (zh) * 2023-08-04 2023-11-07 湖南中晟全肽生化有限公司 靶向Nectin-4的多肽及其用途
CN119701000A (zh) * 2024-12-25 2025-03-28 中国人民解放军空军军医大学 一类多肽偶联药物及其制备方法和应用

Also Published As

Publication number Publication date
AU2020367325A1 (en) 2022-05-26
KR20220088416A (ko) 2022-06-27
EP4045089A1 (en) 2022-08-24
BR112022007099A2 (pt) 2022-07-05
IL292113A (en) 2022-06-01
JP2022552839A (ja) 2022-12-20
WO2021074622A1 (en) 2021-04-22
GB201914872D0 (en) 2019-11-27
US20240173422A1 (en) 2024-05-30
MX2022004572A (es) 2022-05-06
CA3154672A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
CN114901317A (zh) 双环肽配体药物偶联物
CN114521197B (zh) 异串联双环肽复合物
CN111787955B (zh) 特异于EphA2的双环肽配体
CN111183147B (zh) Cd137特异性的双环肽配体
EP3897849A1 (en) Bicyclic peptide ligands specific for pd-l1
CN113260420A (zh) Pd-l1特异性的双环肽配体
CN113383007A (zh) Caix特异性的双环肽配体
US20240398965A1 (en) Bicyclic peptide ligand drug conjugates
CN118234517A (zh) 双环肽配体药物偶联物
HK40120938A (en) Bicyclic peptide ligands specific for epha2
HK40038057A (en) Bicyclic peptide ligands specific for epha2
HK40038057B (en) Bicyclic peptide ligands specific for epha2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220812